PREDICTIVE FACTORS FOR SUCCESSFUL BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS DOSE TAPERING IN RHEUMATOID ARTHRITIS

被引：0
|
作者：
Loh, Min Yi [1 ]
Jones, Claire J. [1 ]
Peall, Adrian [1 ]
Trickey, Jeanette [1 ]
机构：
[1] Wye Valley NHS Trust, Dept Rheumatol, Hereford, England
来源：
RHEUMATOLOGY | 2023年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E075
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Disease-modifying anti-rheumatic drugs improve the cardiovascular profile in patients with rheumatoid arthritis
    Giachi, Andrea
    Cugno, Massimo
    Gualtierotti, Roberta
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [32] Integrating Nanotechnological Advancements of Disease-Modifying Anti-Rheumatic Drugs into Rheumatoid Arthritis Management
    Singh, Sukhbir
    Tiwary, Neha
    Sharma, Neelam
    Behl, Tapan
    Antil, Anita
    Anwer, Md. Khalid
    Ramniwas, Seema
    Sachdeva, Monika
    Elossaily, Gehan M.
    Gulati, Monica
    Ohja, Shreesh
    PHARMACEUTICALS, 2024, 17 (02)
  • [33] Cost-effective analysis of disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Syngle, Ashit
    Kaur, Sudeep
    Verma, Inderjeet
    Syngle, Tanya
    Syngle, Vijaita
    CLINICAL RHEUMATOLOGY, 2017, 36 (08) : 1715 - 1720
  • [34] Cost-effective analysis of disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Ashit Syngle
    Sudeep Kaur
    Inderjeet Verma
    Tanya Syngle
    Vijaita Syngle
    Clinical Rheumatology, 2017, 36 : 1715 - 1720
  • [35] Cardiovascular Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
    Drakopoulou, Maria
    Soulaidopoulos, Stergios
    Oikonomou, George
    Tousoulis, Dimitrios
    Toutouzas, Konstantinos
    CURRENT VASCULAR PHARMACOLOGY, 2020, 18 (05) : 488 - 506
  • [36] Can we discontinue synthetic disease-modifying anti-rheumatic drugs in rheumatoid arthritis?
    Scott, I. C.
    Kingsley, G. H.
    Scott, D. L.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2013, 31 (04) : S4 - S8
  • [37] Therapeutic Utility and Adverse Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs in Inflammatory Arthritis
    Min, Hong Ki
    Kim, Se Hee
    Kim, Hae-Rim
    Lee, Sang-Heon
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (22)
  • [38] IMPACT OF BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN LIPID PROFILE OF PSORIATIC ARTHRITIS PATIENTS
    Guajardo-Aldaco, Andrea L.
    Galarza-Delgado, Dionicio A.
    Azpiri-Lopez, Jose R.
    Colunga-Pedraza, Iris J.
    Cardenas-de la Garza, Jesus A.
    Arvizu-Rivera, Rosa I.
    Elizondo-Benitez, Maria F.
    Gonzalez-Gonzalez, Valeria
    ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [39] Recurrent infections in a rheumatoid arthritis patient with a primary immunodeficiency, treated with conventional and biologic disease-modifying anti-rheumatic drugs
    Diamantopoulos, Andreas P.
    Haugeberg, Glenn
    MODERN RHEUMATOLOGY, 2012, 22 (02) : 295 - 297
  • [40] Two Cases of High Tibial Osteotomy in Patients with Rheumatoid Arthritis Treated with Biologic Disease-modifying Anti-rheumatic Drugs
    Takahara, Yasuhiro
    Nishida, Keiichiro
    Nakashima, Hirotaka
    Ochi, Nobuaki
    Uchida, Yoichiro
    Kato, Hisayoshi
    Itani, Satoru
    Nakamura, Makoto
    Iwasaki, Yuichi
    Tsujimura, Yoshitaka
    ACTA MEDICA OKAYAMA, 2019, 73 (06) : 537 - 542
12345